diagnostics Review Health-Related Quality of Life (HRQoL) in Sarcoidosis: Diagnosis, Management, and Health Outcomes Lesley Ann Saketkoo 1,2,3,4, *, Anne-Marie Russell 5,6, * , Kelly Jensen 1,4,7 , Jessica Mandizha 8 , Jinny Tavee 9 , Jacqui Newton 10 , Frank Rivera 11,12 , Mike Howie 10,13 , Rodney Reese 11,12,14 , Melanie Goodman 15 , Patricia Hart 16 , Bert Strookappe 17,18 , Jolanda De Vries 19,20 , Misha Rosenbach 21 , Mary Beth Scholand 22 , Mathew R. Lammi 1,2,3 , Marjon Elfferich 17,18 , Elyse Lower 23 , Robert P. Baughman 23 , Nadera Sweiss 24 , Marc A. Judson 25 and Marjolein Drent 18,26,27   Citation: Saketkoo, L.A.; Russell, A.-M.; Jensen, K.; Mandizha, J.; Tavee, J.; Newton, J.; Rivera, F.; Howie, M.; Reese, R.; Goodman, M.; et al. Health-Related Quality of Life (HRQoL) in Sarcoidosis: Diagnosis, Management, and Health Outcomes. Diagnostics 2021, 11, 1089. https:// doi.org/10.3390/diagnostics11061089 Academic Editor: Claudio Tana Received: 30 April 2021 Accepted: 2 June 2021 Published: 15 June 2021 Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affil- iations. Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). 1 New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA 70112, USA; kjensen1@tulane.edu (K.J.); mlammi@lsuhsc.edu (M.R.L.) 2 Comprehensive Pulmonary Hypertension Center and Interstitial Lung Disease Clinic Programs, University Medical Center, New Orleans, LA 70112, USA 3 Section of Pulmonary Medicine, Louisiana State University School of Medicine, New Orleans, LA 70112, USA 4 Tulane University School of Medicine, Tulane University, New Orleans, LA 70112, USA 5 College of Medicine and Health, University of Exeter, Devon EX1 2LU, UK 6 Imperial College Healthcare NHS Foundation Trust, London W2 1NY, UK 7 Department of Internal Medicine, Oregon Health and Science University, Portland, OR 97239, USA 8 Respiratory Medicine, Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter EX2 5DW, UK; jessica.mandizha@nhs.net 9 Department of Neurology, National Jewish Health, Denver, CO 80206, USA; taveej@njhealth.org 10 Sarcoidosis UK, China Works, Black Prince Road, London SE1 7SJ, UK; jacquijnewton@gmail.com (J.N.); mikesarco73@gmail.com (M.H.) 11 Foundation for Sarcoidosis Research, Chicago, IL 60614, USA; fjr311@gmail.com (F.R.); rreese1956@gmail.com (R.R.) 12 National Sarcoidosis Support Group, Stronger than Sarcoidosis, New York, NY 11727, USA 13 CGI UK, Space Defense & Intelligence (Cyber Security Operations), London EC3M 3BY, UK 14 Sarcoidosis Awareness Foundation of Louisiana, Baton Rouge, LA 70812, USA 15 New Orleans Sarcoidosis Support Group, New Orleans, LA 70112, USA; nosarcoidosis@gmail.com 16 iHart Wellness Holistic Approach to Sarcoidosis Certified Health & Wellness Coach, International Association of Professionals, New York, NY 11727, USA; pebhart@gmail.com 17 Department of Physiotherapy, Gelderse Vallei Hospital, 10, 6716 RP Ede, The Netherlands; strookappeb@zgv.nl (B.S.); marjon.elfferich@hetnet.nl (M.E.) 18 ildcare Foundation Research Team, 6711 NR Ede, The Netherlands; m.drent@hetnet.nl (M.D.) 19 Admiraal de Ruyter Hospital (Adrz), 114, 4462 RA Goes, The Netherlands; jolanda.devries@adrz.nl 20 Department of Medical and Clinical Psychology, Tilburg University, 5037 AB Tilburg, The Netherlands 21 Cutaneous Sarcoidosis Clinic, Department of Dermatology, University of Pennsylvania, Philadelphia, PA 19104, USA; Misha.Rosenbach@pennmedicine.upenn.edu 22 Division of Pulmonary Medicine, Interstitial Lung Disease Center, University of Utah, Salt Lake City, UT 84132, USA; scholand@genetics.utah.edu 23 Department of Medicine, University of Cincinnati Medical Center, Cincinnati, OH 45267, USA; lowere@ucmail.uc.edu (E.L.); BAUGHMRP@ucmail.uc.edu (R.P.B.) 24 Division of Rheumatology, Department of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA; nsweiss@uic.edu 25 Division of Pulmonary Medicine and Critical Care, Albany Medical College, Albany, NY 12208, USA; JudsonM@amc.edu 26 Interstitial Lung Diseases (ILD) Center of Excellence, Department of Pulmonology, St. Antonius Hospital, Koekoekslaan 1, 3435 CM Nieuwegein, The Netherlands 27 Department of Pharmacology and Toxicology, Faculty of Health and Life Sciences, Maastricht University, 40, 6229 ER Maastricht, The Netherlands * Correspondence: lsaketk@tulane.edu (L.A.S.); a.russell4@exeter.ac.uk (A.-M.R.) Abstract: Health-related quality of life (HRQoL), though rarely considered as a primary endpoint in clinical trials, may be the single outcome reflective of patient priorities when living with a health condition. HRQoL is a multi-dimensional concept that reflects the degree to which a health condition interferes with participation in and fulfillment of important life areas. HRQoL is intended to capture Diagnostics 2021, 11, 1089. https://doi.org/10.3390/diagnostics11061089 https://www.mdpi.com/journal/diagnostics